

PRODUCT MONOGRAPH

pms-ASA

(Acetylsalicylic acid chewable tablets, USP)

81 mg

Praxis ASA EC 81 mg Daily Low Dose

(Acetylsalicylic acid delayed-release tablets, USP)

81 mg

Platelet aggregation inhibitor

Pharmascience, Inc
6111 Royalmount Ave # 100
Montreal, Quebec
H4P 2T4

Date of Preparation:
July 18, 2006
Date of Revision:
July 30, 2009

Control No. 131594

PRODUCT MONOGRAPH

pms-ASA

(Acetylsalicylic acid chewable tablets, USP)

81 mg

Praxis ASA EC 81 mg Daily Low Dose

(Acetylsalicylic acid delayed release tablets, USP)

81 mg

THERAPEUTIC OR PHARMACOLOGICAL CLASSIFICATION

Platelet aggregation inhibitor.

ACTION AND CLINICAL PHARMACOLOGY

ASA interferes with the production of prostaglandins in various organs and tissues through acetylation of the enzyme cyclo-oxygenase. Prostaglandins are themselves powerful irritants and produce headaches and pain on injection in man. Prostaglandins also appear to sensitize pain receptors to other noxious substances such as histamine and bradykinin. By preventing the synthesis and release of prostaglandins in inflammation, ASA may avert the sensitization of pain receptors.

The antipyretic activity of ASA is due to its ability to interfere with the production of prostaglandin E₁ in the brain. Prostaglandin E₁ is one of the most powerful pyretic agents known.

The inhibition of platelet aggregation by ASA is due to its ability to interfere with the production of thromboxane A₂ within the platelet. Thromboxane A₂ is largely responsible for the aggregating properties of platelets.

INDICATIONS AND CLINICAL USE

Acetylsalicylic acid (ASA) is indicated for the following uses, based on its platelet aggregation inhibitory properties:

- For reducing the risk of morbidity and death in patients with unstable angina and in those with previous myocardial infarction.

- For reducing the risk of transient ischemic attacks (TIA) and for secondary prevention of atherothrombotic cerebral infarction;

In addition, pms-ASA 81 mg and Praxis ASA EC 81 mg Daily Low Dose 81 mg are also indicated for the following uses, based on its platelet aggregation inhibitory properties:

- For reducing the risk of vascular mortality in patients with a suspected acute myocardial infarction.

- For reducing the risk of a first non-fatal myocardial infarction in individuals deemed to be at sufficient risk of such an event by their physician. There is no evidence for a reduction in the risk of first fatal myocardial infarction. ASA does not reduce the risk of either cardiovascular mortality or first strokes, fatal or non-fatal. The decrease in the risk of first non-fatal myocardial infarction must be assessed against a much smaller but significant increase in the risk of haemorrhagic stroke as well as gastrointestinal bleeding.

CONTRAINDICATIONS

Use of pms-ASA 81 mg and Praxis ASA EC 81 mg Daily Low Dose 81 mg is contraindicated in patients:

- who are hypersensitive to this drug or to any ingredient in the formulation or component of the container. For a complete listing, see COMPOSITION and AVAILABILITY OF DOSAGE FORMS sections of the product monograph.
- with a history of asthma induced by the administration of salicylates or substances with a similar action, notably non-steroidal anti-inflammatory drugs
- also taking methotrexate at doses of 15 mg/week or more
- during their last trimester of pregnancy
- with any Hemorrhagic diathesis
- with an Active peptic ulcer.

WARNINGS AND PRECAUTIONS

General

ASA is one of the most frequent causes of accidental poisonings in toddlers and infants. Tablets should be kept well out of the reach of children.

Salicylates should be administered cautiously to patients with:

- Hypersensitivity to anti-inflammatory or antirheumatic drugs or other allergens
- impaired renal function or hepatic function
- a history of chronic or recurrent gastrointestinal ulcerations and bleeds
- a history of bleeding tendencies, significant anemia and/or hyp thrombinemia

Hypersensitivity

Acetylsalicylic acid (ASA) may precipitate bronchospasm and induce asthma attacks or other hypersensitivity reactions. Risk factors are present bronchial asthma, hay fever, nasal polyps, or chronic respiratory disease. This applies also for patients showing allergic reactions (e.g. cutaneous reactions, itching, urticaria) to other substances.

Hematologic

Due to effect on platelet aggregation, ASA may be associated with an increased risk of bleeding. Caution is necessary when salicylates and anticoagulants are prescribed concurrently, as salicylates can depress the concentration of prothrombin in the plasma.

Peri-Operative Considerations

Due to its inhibitory effect on platelet aggregation ASA may lead to an increased bleeding tendency during and after surgical operations (including minor surgeries, e.g. dental extractions).

Special Populations

Pregnant Women:

Use of salicylates in the first 3 months of pregnancy has been associated in several epidemiological studies with an elevated risk of malformations (cleft palate, heart malformations). After normal therapeutic doses this risk seems to be low: a prospective study with exposure of about 32,000 mother-child pairs has not yielded any association with the risk of malformations.

Salicylates should be taken during pregnancy only after strict risk benefit evaluation.

In the last 3 months of pregnancy, administration of salicylates in high doses (>300mg/day) can lead to prolongation of the gestation period, premature closure of the arterial duct and inhibition of uterine contractions. An increased hemorrhagic tendency has been observed in both mother and child.

Administration of ASA in high doses (> 300 mg/d) shortly before birth, can lead to intracranial hemorrhages, particularly in premature babies.

Nursing Women:

Acetylsalicylic acid (ASA) and its metabolites pass into breast milk in small quantities. Since no adverse effects on the infant have been observed after occasional use, interruption of breast-

feeding is usually unnecessary. However, on regular use or on intake of high doses, breast feeding should be discontinued early.

Pediatrics:

A possible association between Reye's syndrome and the use of salicylates has been suggested but not established. Reye's syndrome has also occurred in many patients not exposed to salicylates. Acetylsalicylic acid (ASA) should not be used in children and teenagers for viral infections with or without fever without consulting a physician. In certain viral illnesses, especially influenza A, influenza B and varicella, there is a risk of Reye's syndrome, a very rare but possibly life-threatening illness requiring immediate medical action. The risk may be increased when ASA is given concomitantly; however, no causal relationship has been proven. Should persistent vomiting occur with such diseases; this may be a sign of Reye's syndrome.

Low Uric Acid Excretion:

At low doses, ASA reduces excretion of uric acid. This can trigger gout in patients who already tend to have low uric acid excretion.

Monitoring and Laboratory Tests:

Salicylates can produce changes in thyroid function tests.

Isolated cases of liver function disturbances (transaminases increase) have been described.

ADVERSE REACTIONS

Many adverse reactions due to ASA ingestion are dose-related. The following is a list of adverse reactions that have been reported in the literature and from both clinical and post-marketing experience.

Gastrointestinal: (the frequency and severity of these adverse effects are dose-related): nausea, vomiting, diarrhea, gastrointestinal bleeding and/or ulceration, dyspepsia, heartburn, hematemesis and melena.

Ear: tinnitus, vertigo, hearing loss.

Hematologic: leukopenia, thrombocytopenia, purpura, anemia.

Dermatologic and hypersensitivity: urticaria, angioedema, pruritus, skin eruptions, asthma, anaphylaxis.

Miscellaneous: mental confusion, drowsiness, sweating, thirst.

DRUG INTERACTIONS

Overview

Acetylsalicylic acid (ASA) should be used with caution with other products that have anticoagulation or antiplatelet effects, as these effects may be potentiated. Drugs that bind to protein binding sites should also be used cautiously since ASA may displace drugs from their protein, binding site.

Methotrexate, used at 15mg/week or less: Salicylates may retard the elimination of methotrexate by decreasing renal clearance of methotrexate, displacing methotrexate from protein binding sites, and thereby increasing its hematological toxicity.

Anti-coagulants, e.g. warfarin, heparin: Caution is necessary when salicylates and anticoagulants are prescribed concurrently, as salicylates can depress the concentration of prothrombin in the plasma.

Oral hypoglycemics, e.g. insulin, sulfonylureas: Large doses of salicylates have a hypoglycemic action and may enhance the effect of oral hypoglycemic agents. Diabetics receiving concurrent salicylate and hypoglycemic therapy should be monitored closely; reduction of the sulfonylurea hypoglycemic drug dosage may be necessary.

Diuretics: Sodium excretion produced by spironolactone may be decreased by salicylate administration.

Uricosuric Agents: Salicylates in large doses are uricosuric agents; smaller amounts may depress uric acid clearance and thus decrease the uricosuric effects of other drugs.

Valproic Acid: Salicylates may alter valproic acid (VPA) metabolism and may displace VPA from protein binding sites, possibly intensifying the effects of VPA. Caution is recommended when VPA is administered concomitantly with salicylates.

Glucocorticoids (systemic), except hydrocortisone used as replacement therapy in Addison's disease: Decreased blood salicylate levels during corticosteroid treatment and risk of salicylate overdose after this treatment is stopped via increased elimination of salicylates by corticosteroids.

Angiotensin Converting Enzyme (ACE) Inhibitors: The hyponatremic and hypotensive effects of ACE inhibitors may be diminished by the concomitant administration of ASA due to its indirect effect on the rennin-angiotensin conversion pathway. The potential interaction may be related to the dose of ASA (3g/day or more).

Digoxin: Plasma concentrations of digoxin are increased due to a decrease in renal excretion.

ASA and other NSAIDs:

The use of other non-steroidal anti-inflammatory drugs with salicylates at high doses ($\geq 3\text{g/day}$) may increase the risk of ulcers and gastrointestinal bleeding due to a synergistic effect.

Ibuprofen: Ibuprofen may interfere with the cardioprotective effects and platelet aggregation inhibitory properties of ASA. Patients should talk to their doctor if they are on an ASA regimen and take ibuprofen for pain. Studies have shown that single doses and multiple doses of ibuprofen may interfere with the anti-platelet effects of low dose ASA.

Drug-Food Interactions

Interactions with food have not been established.

Drug-Herb Interactions

Interactions with herb have not been established.

Drug-Laboratory Interactions

Salicylates can produce changes in thyroid function tests.

Drug-Lifestyle Interactions

Patients taking ASA daily are at an increased risk of developing gastrointestinal bleeding following the ingestion of alcohol.

DOSAGE AND ADMINISTRATION

Platelet aggregation inhibitor:

- For suspected acute myocardial infarction: An initial dose of at least 160 -162.5 mg chewed or crushed to ensure rapid absorption as soon as a myocardial infarction is suspected. The same dose should be given as maintenance over the next 30 days. After 30 days, consider further therapy based on dosage and administration for prevention of recurrent MI (see Prior Myocardial Infarction).
- For the prevention of a first non-fatal myocardial infarction: 80 - 325 mg daily according to the individual needs of the patient, as determined by the physician.
- For reducing the risk of morbidity and death in patients with unstable angina and in those with previous myocardial infarction: 80 - 325 mg daily according to the individual needs of the patient, as determined by the physician.
- For reducing the risk of transient ischemic attacks (TIA) and for secondary prevention of atherothrombotic cerebral infarction: 80 - 325 mg daily according to the individual needs of the patient, as determined by the physician.


PHARMACEUTICAL INFORMATION

Drug Substance

Proper Name: Acetylsalicylic acid

Chemical Names: 2-(Acetyloxy) benzoic acid;
Salicylic acid acetate.

Structure:



Molecular Formula: C₉H₈O₄

Molecular Weight: 180.16

Description: White granules, commonly tabular or needle-like, or white crystalline powder. Odorless or having a faint odor.

Solubility: Slightly soluble in water; freely soluble in alcohol; soluble in chloroform and ether; sparingly soluble in absolute ether.

pK value (25°C): 3.49

Melting Point: 135°C (rapid heating)

COMPOSITION

pms-ASA: Each chewable tablet contains 81 mg acetylsalicylic acid as active ingredient. Non-medicinal ingredients: DC Yellow #10, FDC Red #40, mannitol, orange flavor, pregelatinized starch, sodium saccharin, stearic acid.

Praxis ASA EC 81 mg Daily Low Dose:

Each enteric-coated tablet contains 81 mg acetylsalicylic acid as active ingredient. Non-medicinal ingredients: Colloidal silicon dioxide, FD & C Blue #1, hydroxypropyl methylcellulose, lactose, methacrylic acid copolymer type C, methylated silica, methylcellulose, polydimethylsiloxane, polyethylene glycol, pregelatinized starch, siliconemulsion, sodium lauryl sulfate, sorbitan tristearate, stearic acid, talc, titanium dioxide, triethyl citrate.

AVAILABILITY OF DOSAGE FORM

pms-ASA: Each chewable, salmon coloured, round, biconvex tablet, embossed “ASAPHEN 81” contains 81 mg acetylsalicylic acid. In packages of 30 and 120 tablets.

Praxis ASA EC 81 mg Daily Low Dose Each round, blue coated tablet contains 81 mg acetylsalicylic acid. In packages of 24, 30, 100, 120, 150, 180, 225, 250 255 and 1000 tablets and in blister packs of 7 tablets.

STABILITY AND STORAGE RECOMMENDATIONS

Store at room temperature (15°-30°C).

**PATIENT INFORMATION TO BE DISTRIBUTED ONLY BY
PHYSICIANS/PHARMACISTS**

pms-ASA 81 mg

(Acetylsalicylic Acid Tablets USP)

Praxis ASA EC 81 mg Daily Low Dose 81 mg

(Acetylsalicylic Acid Delayed Release Tablets USP)

This leaflet is a summary and will not tell you everything about **pms-ASA 81 mg** and **Praxis ASA EC 81 mg Daily Low Dose 81 mg**. Contact your doctor or pharmacist if you have any questions about the drug.

This section provides you with information about **pms-ASA 81 mg** acetylsalicylic acid (chewable) tablets, **Praxis ASA EC 81 mg Daily Low Dose 81 mg** acetylsalicylic acid (enteric coated) tablets and how to take this medication. *Please read carefully before you take this medication.*

Your physician has recommended **pms-ASA 81 mg** or **Praxis ASA EC 81 mg Daily Low Dose 81 mg** for doctor-supervised adult long-term preventative therapy.

Follow your physician's instructions concerning the use of **pms-ASA 81 mg** or **Praxis ASA EC 81 mg Daily Low Dose 81 mg** as well as any lifestyle changes, e.g. diet and/or exercise, that he/she may have recommended. Always contact your physician if you experience any difficulties while taking this product.

pms-ASA 81 mg or **Praxis ASA EC 81 mg Daily Low Dose 81 mg** contains acetylsalicylic acid, commonly referred to as ASA, as its active ingredient. Plain (uncoated) ASA, particularly when taken regularly, may cause stomach upset in some people. The special enteric coating of **Praxis ASA EC 81 mg Daily Low Dose 81 mg** tablets allows them to pass intact through the stomach and on into the intestine before they dissolve which may reduce the risk of stomach upset.

Your physician has specifically recommended **pms-ASA 81 mg** or **Praxis ASA EC 81 mg Daily Low Dose 81 mg** because it contains a special, low-dose, formulation of ASA. Other medications such as acetaminophen or ibuprofen that are meant to relieve pain do not have the same preventative action as **pms-ASA 81 mg** or **Praxis ASA EC 81 mg Daily Low Dose 81 mg** which has been specifically formulated for your condition.

DIRECTIONS FOR USE

It is very important that you take this medication as directed by your physician. If you have not seen a physician, do not take this medication until you have done so.

Dosage:

1 to 4 tablets daily of **pms-ASA 81 mg** or **Praxis ASA EC 81 mg Daily Low Dose 81 mg**, depending on your doctor's instructions. You should take this medication at the same time every day to help you to remember to take it. For maximum effectiveness, it is very important to take **pms-ASA 81 mg** or **Praxis ASA EC 81 mg Daily Low Dose 81 mg** every day, as directed by your physician. Do not take more tablets than your physician recommends.

Praxis ASA EC 81 mg Daily Low Dose 81 mg tablets must be swallowed whole for the medication to work properly. Praxis ASA EC 81 mg Daily Low Dose 81 mg tablets have a special enteric coating designed to help prevent stomach upset. To benefit from this protection, the tablets should not be crushed or broken unless in the case of a heart attack. pms-ASA 81 mg tablets are chewable and therefore must be chewed well and swallowed.

NON-MEDICINAL INGREDIENTS

pms-ASA 81 mg

DC Yellow #10, FDC Red #40, mannitol, orange flavor, pregelatinized starch, sodium saccharin, stearic acid.

Praxis ASA EC 81 mg Daily Low Dose 81 mg

Colloidal silicon dioxide, FD & C Blue #1, hydroxypropyl methylcellulose, lactose, methacrylic acid copolymer type C, methylated silica, methylcellulose, polydimethylsiloxane, polyethylene

glycol, pregelatinized starch, silicon emulsion, sodium lauryl sulfate, sorbitan tristearate, stearic acid, talc, titanium dioxide, triethyl citrate.

ANSWERS TO COMMONLY ASKED QUESTIONS

WHY WAS ASA RECOMMENDED BY MY DOCTOR?

FOR PREVENTION OF A SECOND HEART ATTACK OR STROKE (DAILY THERAPY)

It can be used to prevent a second stroke or heart attack. If you have experienced either a stroke or a heart attack you may be at risk for a second one. There are certain risk factors that can place you at an increased risk:

- | | |
|---------------------------------|-------------------------|
| -Overweight | -Stress |
| -Smoking | -High blood cholesterol |
| -Inactive (sedentary) lifestyle | -High blood pressure |

These can be discussed with your physician in order to complement the effectiveness of pms-ASA 81 mg or Praxis ASA EC 81 mg Daily Low Dose 81 mg.

Your doctor may recommend changes in diet, exercise and lifestyle for your benefit in avoiding a second heart attack or stroke.

If you experience any difficulties with your treatment always discuss with your doctor or pharmacist.

USE DURING A HEART ATTACK

If you think you are having a heart attack, call an ambulance immediately, and chew (pms-ASA 81 mg) or crush (Praxis ASA EC 81 mg Daily Low Dose 81 mg) and ingest 2 tablets. It is important to chew or crush the product, to ensure this medicine works quickly. Then get to a hospital immediately for medical attention. Taking ASA at the first signs and symptoms can reduce your risk of dying from the heart attack.

The signs and symptoms of a heart attack include:

1. uncomfortable pressure, fullness, squeezing or pain in the center of the chest that lasts more than a few minutes, or goes away quickly and comes back,
2. pain that spreads to the shoulders, neck or arms,
3. chest discomfort with lightheadedness, fainting, sweating, nausea or shortness of breath.

At the hospital, the doctor will then recommend appropriate therapy

WHAT IF I FORGET TO TAKE MY MEDICATION?

If you forget to take your medication at the usual time, take it when you remember. Do not take extra medication to compensate for a missed dosage unless instructed by your physician.

SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Like all medication, ASA may occasionally produce unwanted side effects. You should call your doctor if you experience any of the following: nausea, vomiting, stomach irritation, ringing or buzzing in the ears or pain, or if you notice that you are bruising more easily than you were before starting a daily dose of ASA.

Regular daily use of alcohol while on ASA daily therapy may increase your risk of developing gastrointestinal bleeding.

SERIOUS SIDE EFFECTS AND WHAT TO DO ABOUT THEM

Stop use and call your doctor if you experience an allergic reaction (skin rash, hives, itching or breathing difficulties); stomach bleeding, loss of hearing or bleeding.

WHEN IT SHOULD NOT BE USED

ASA should not be used if you:

- Are allergic to ASA or any ingredient within the formulation.

- Have an active stomach ulcer
- Have a history of asthma induced by salicylates or other anti-inflammatory drugs
- Are using methotrexate at doses of 15mg/week or more
- Are in the last trimester of pregnancy
- Are prone to bleeding.

WHAT ELSE SHOULD I KNOW BEFORE TAKING THIS MEDICINE?

Your doctor will ask you many questions about your health, lifestyle, and medications before recommending pms-ASA 81 mg or Praxis ASA EC 81 mg Daily Low Dose 81 mg.

This is why it is very important that you tell your doctor all such information. If you have forgotten to tell your doctor about any of the following, call your doctor or pharmacist before you take this medicine.

- Allergy to salicylates
- Asthma
- Stomach problems
- Peptic ulcer
- Severe liver/kidney disease
- Severe anemia
- Are pregnant or breast-feeding
- Will be having surgery in five to seven days
- Are taking other medications containing salicylates or acetaminophen
- Are taking anti-inflammatory drugs, anticonvulsants, anti-diabetics or gout medication
- Are taking or planning to take this medication while consuming alcohol
- History of blood clotting defects or receiving blood thinners

Ibuprofen may interfere with the protective benefits of ASA. Talk to your doctor if you are on an ASA regimen and taking ibuprofen for pain.

CAUTION

This product is not recommended for children or teenagers. This package contains enough drug to seriously harm a child. Keep out of children's reach. Do not administer to children and teenagers for chicken pox or flu symptoms before a doctor is consulted. Reye's syndrome, which can occur in children or teenagers, is a rare but serious illness reported to be associated with ASA.

It is especially important not to use this medication during the last 3 months of pregnancy unless specifically directed to do so by your physician because it may cause problems in the unborn child or complications during delivery.

Call your doctor before taking this drug when nursing.

In case of accidental overdose call a doctor or hospital immediately, even if there are no symptoms.

HOW TO STORE IT

Keep out of reach of children

Store at room temperature 15-30°C

REPORTING SUSPECTED SIDE EFFECTS

To monitor drug safety, Health Canada through the Canada Vigilance Program collects information on serious and unexpected effects of drugs. If you suspect you have had a serious or unexpected reaction to this drug you may notify Canada Vigilance by:

Toll-free telephone: 866-234-2345

Toll-free fax: 866-678-6789

Online: www.healthcanada.gc.ca/medeffect

By email: CanadaVigilance@hc-sc.gc.ca

By regular mail:

Canada Vigilance National Office

Marketed Health Products Safety and Effectiveness

Information Bureau

Marketed Health Products Directorate

Health Products and Food Branch

Tunney's Pasture, AL 0701C

Ottawa ON K1A 0K9

NOTE: Should you require information related to the management of the side effects, please contact your health care provider before notifying Canada Vigilance. The Canada Vigilance Program does not provide medical advice.

Product Monograph is available to health professionals upon request.

For further information or questions about this product, contact Pharmascience Inc., Montreal, Canada at their Medical Information Hotline between 8:30 am and 4:30 pm, Eastern Standard Time, Monday to Friday. Call toll-free at 1-888-550-6060.

PHARMACOLOGY

Absorption, distribution, metabolism and excretion:

When ASA is taken orally, it is rapidly absorbed from the stomach and proximal small intestine. The gastric mucosa is permeable to the non-ionized form of acetylsalicylic acid, which passes through the stomach wall by a passive diffusion process.

Optimum absorption of salicylate in the human stomach occurs in the pH range of 2.15 to 4.10.

Absorption in the small intestine occurs at a significantly faster rate than in the stomach. After an oral dose of 0.65 g ASA, the plasma acetylsalicylate concentration in man usually reaches a level between 0.6 and 1.0 mg% in 20 minutes after ingestion and drops to 0.2 mg% within an hour. Within the same period of time, half or more of the ingested dose is hydrolyzed to salicylic acid by esterases in the gastrointestinal mucosa and the liver, the total plasma salicylate concentration reaching a peak between one or two hours after ingestion, averaging between 3 and 7 mg%. Many factors influence the speed of absorption of ASA in a particular individual at a given time; tablet disintegration, solubility, particle size, gastric emptying time, psychological state, physical condition, nature and quantity of gastric contents, etc., all affect absorption.

Distribution of salicylate throughout most body fluids and tissues proceeds at a rapid rate after absorption. Aside from the plasma itself, fluids which have been found to contain substantial amounts of salicylate after oral ingestion include spinal, peritoneal and synovial fluids, saliva and milk. Tissues containing high concentrations of the drug are the kidney, liver, heart and lungs. Concentrations in the brain are usually low, and are minimal in feces, bile and sweat.

The drug readily crosses the placental barrier. At clinical concentrations, from 50% to 90% of the salicylate is bound to plasma proteins especially albumin, while acetylsalicylic acid itself is bound to only a very limited extent. However, ASA has the capacity of acetylating various proteins, hormones, DNA, platelets and hemoglobin, which at least partly explains its wide-ranging pharmacological actions.

The liver appears to be the principal site for salicylate metabolism, although other tissues may also be involved. The three chief metabolic products of ASA or salicylic acid are salicyluric acid, the ether or phenolic glucuronide and the ester or acyl glucuronide. A small fraction is also converted to gentisic acid and other hydroxybenzoic acids. The half-life of ASA in the circulation is from 13 to 19 minutes so that the blood level drops quickly after absorption is complete. However, the half-life of the salicylate ranges between 3.5 and 4.5 hours, which means that 50% of the ingested dose leaves the circulation within that time.

Excretion of salicylates occurs principally via the kidney, through a combination of glomerular filtration and tubular excretion, in the form of free salicylic acid, salicyluric acid, as well as phenolic and acyl glucuronides. Salicylate can be detected in the urine shortly after its ingestion but the full dose requires up to 48 hours for complete elimination. The rate of excretion of free salicylate is extremely variable, reported recovery rates in human urine ranging from 10% to 85%, depending largely on urinary pH. In general, it can be stated that acid urine facilitates reabsorption of salicylate by renal tubules, while alkaline urine promotes excretion of the drug.

Effects on platelets: relation to hemostasis and thrombosis.

Platelets play an important role in normal hemostasis and clinical pathologic and experimental evidence indicates that their aggregation may play an equally important role in the evolution of a variety of disease states including cerebrovascular disease, ischemic heart disease and myocardial infarction. ASA inhibits platelet aggregation by irreversibly acetylating platelet cyclo-oxygenase, thereby blocking the production of prostaglandin endoperoxides PGG₂ and PGH₂ which are precursors of the major platelet-aggregating material, thromboxane A₂, which is also a powerful vasoconstrictor. However, ASA does not prevent the adherence of platelets to damaged vessel walls or the release of granule contents from these adherent platelets. As the anuclear platelets are unable to synthesize new enzyme molecules to replace those that have been inactivated, inhibition of platelet aggregation by ASA thus persist for the life of the platelets.

Daily administration of 20 to 40 mg of ASA to healthy volunteers reduced platelet

thromboxane production but inhibited platelet aggregation only partially. When administered to patients recovering from myocardial infarction, 50 mg ASA daily had the same effects on thromboxane production, platelet aggregation and bleeding times as 324 mg daily. Other studies show that ASA doses of 40 to 325 mg daily suppressed thromboxane production by at least 80 %, but 80 mg ASA daily was the lowest dose required for maximum cumulative thrombocyte function inhibition. The protective effect of ASA against experimentally induced thrombosis or atherosclerosis has been demonstrated in several animal models.

Besides inhibiting the biosynthesis of thromboxane A_2 by platelets, ASA also interferes with the production of prostacyclin (PGI_2) by vascular endothelial cells, the above-mentioned prostaglandin endoperoxides being common precursors of both thromboxane A_2 and prostacyclin. This latter compound is one of the most powerfully acting platelet deaggregators and vasodilators and thus it would appear that the interference with the hemostatic processes by ASA depends on the thromboxane-prostacyclin balance. In fact, it has been suggested that under some conditions, high doses of ASA may be thrombogenic. However, in contrast to platelets, the vascular endothelial cells are able to regenerate cyclo-oxygenase in a relatively short time and therefore therapeutic doses of ASA are likely to produce a lesser inhibition of the vascular prostacyclin system than of the platelet thromboxane-forming mechanism. In fact, there is no clinical evidence to indicate that high doses of ASA would result in an increased risk of thromboembolism. Indeed, quite the contrary was observed and, in a controlled study, paradoxical shortening of the bleeding time was not observed at a daily ASA dose 3.6 g. Lower dosages of ASA make selective blocking of the TxA_2 -synthesis without a simultaneous blocking of PGI_2 -production possible.

The use of ASA in patients with a suspected acute myocardial infarction was investigated in a large multicenter trial involving over 17,000 patients. Treatment with ASA resulted in a 23% reduction in the risk of vascular mortality versus placebo at 5 weeks. This use translates to a reduction of 24 deaths and 14 non-vascular events per 1000 patients treated.

The effect of time to therapy revealed that patients treated with ASA “early” (0 to 4 hours) versus “late” (5 to 24 hours) after symptom onset experienced reductions in the odds of vascular death of 25% versus 21%, versus placebo at 5 weeks. ‘Early’ treatment with ASA resulted in the saving of 4 additional lives per 1000 patients versus ‘late’ treatment.

Long term follow-up (up to 10 years) of patients in this study established that the early survival advantage to ASA persisted long term, and that this prolonged benefit was additive to that of fibrinolytic therapy.

The use of ASA for secondary prevention of thrombotic events is supported by a comprehensive overview of a number of clinical trials involving patients who already had some type of vascular disease (myocardial infarction, unstable angina, stroke or transient cerebral ischemia). Overall, these studies point to a 26-28% reduction of the combined endpoints of MI, stroke, or vascular deaths by treatment with ASA alone at doses of 75 to 325 mg daily. Studies which directly compared low doses with higher doses (30-1200 mg/day), indicated that the incidence of gastrointestinal adverse effects were significantly less common with the lower doses.

Recent discussions have focused on the efficacy of ASA for the primary prevention of myocardial infarction and stroke. Two large scale randomized trials, aimed at evaluating prophylactic use of ASA, were conducted among apparently healthy male physicians (22,000 in the United States and 5,000 in the United Kingdom respectively and their results have been published. In the summary overview of the combined results presented by the principal investigators, the authors state that:

“...Taken together, these two primary-prevention studies demonstrate a significant ($P < 0.0001$) reduction in nonfatal myocardial infarction of about one third.”

On the other hand, the same two studies have not indicated any reduction in overall vascular

mortality and also suggested a slight increase in the risk of non-fatal disabling stroke. Current controversy exists about the applicability of these findings, obtained in a selected population, to the general public. As well, the optimum dosage regimen still remains an open question in this regard. Thus, the use of ASA for primary prevention should remain, in the words of the principal investigators:

“A matter of judgment in which the physician considers the cardiovascular risk profile of the patient and balances the known hazards of aspirin...against the clearly established reduction in the incidence of a first myocardial infarction.”

TOXICOLOGY

The clinical and pathological signs of poisoning from toxic and lethal oral doses of ASA have been extensively described for man, much less extensively for other species.

The acute toxicity of ASA in animals has been studied and reviewed in detail by Boyd. The signs of poisoning in rats from doses in the lethal range are due to varying degrees of gastroenteritis, hepatitis, nephritis, pulmonary edema, encephalopathy, shock and minor toxic effects on other organs and tissues. Death is due to convulsions or cardiovascular shock. The major difference between species appears to be the ability to vomit toxic doses seen in man, cats and dogs, but not in mice, rats and rabbits. Otherwise, the pathological reaction to toxic doses of ASA is similar in all species in which such studies have been reported. The acute oral LD₅₀ values have been reported as being over 1.0 g/kg in man, cat and dog, 0.92 g/kg in female and 1.48 g/kg in male albino rats, 1.19 g/kg in guinea pig, 1.1 g/kg in mouse and 1.8 g/kg in rabbit.

Chronic toxicity studies were reported in mice and rats. When ASA was administered at 2 to 20 times the maximum tolerated clinical dose to mice for up to one year, a dose-related deleterious effect was observed on mean survival time, number of young born and number of young raised to wearing age, no evidence of carcinogenic effect was found.

The chronic oral LD₅₀ in male albino rats has been reported as 0.24g/kg/day when given for 100 days. At these daily doses ASA produced no anorexia and no loss of body weight. It did produce polydipsia, aciduria, diuresis, drowsiness, hyperreflexia, piloerection, rapid and deep respiration, tachycardia, and during the second month, soft stools, epistaxis, sialorrhea, dacryorrhea and death in hypothermic coma. Autopsy disclosed the presence of a hypertrophied stomach, renal congestion, mild hepatitis and pneumonitis. While teratogenic effects were noted in animals at near lethal doses, there is no evidence to indicate that ASA is teratogenic in man.

BIBLIOGRAPHY

1. Abbott F, Kassam J, Orr J, and K. Farrell, The effects of aspirin on valproic acid metabolism. *Clin. Pharmacol. Ther.* 1986;40:94-100.
2. Altman R, Bouillon F, Rouvier J, Raca R, de la Fuente, Favaloro R. Aspirin and prophylaxis of thromboembolic complications in patients with substitute heart valves. *J Thorac Cardiovasc Surg* 1976; 72: 127-9.
3. Amrein PC, Ellman L, Harris WH. ASPIRIN prolongation of bleeding time and perioperative blood loss. *JAMA* 1981; 245: 1825-8.
4. Antiplatelet Trialists' Collaboration. Secondary prevention of vascular disease by prolonged antiplatelet treatment. *Br Med J* 1988; 296: 320-1.
- 5a Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. *Br Med J* 1994; 308: 81-106.
- 5b Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - II: Maintenance of vascular graft or arterial patency by antiplatelet therapy. *Br Med J* 1994; 308: 158-68.
- 5c Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy - III: Reduction in venous thrombosis and pulmonary embolism by antiplatelet prophylaxis among surgical and medical patients. *Br Med J* 1994; 308: 235-46.
6. Aspirin Myocardial Infarction Study Research Group. A randomized controlled trial of aspirin in persons recovered from myocardial infarction. *JAMA* 1980; 243: 661-9.
7. Aspirin Myocardial Infarction Study Research Group: The aspirin myocardial infarction study: final results. *Circulation* 1980; 62 (Suppl V): V79-V84.
8. Bailey JM. Prostacyclins, thromboxane and cardiovascular disease. *Tr Biochem Sci* 1979; 4: 68-71.
9. Boston Collaborative Drug Surveillance Group. Regular aspirin intake and acute myocardial infarction. *Br Med J* 1974; 1: 440-3.
10. Bousser MG, Eschwege E, Haguenu M, Lefauconnier JM, Thibult N, et al. "AICLA" controlled trial of aspirin and dipyridamole in the secondary prevention of atherothrombotic cerebral ischemia. *Stroke* 1983; 14:5-14.

11. Boyd EM. Analgesic abuse. Maximal tolerated daily doses of acetylsalicylic acid. *Can Med Ass J* 1968; 99: 790-8.
12. Boyd EM. The acute oral toxicity of acetylsalicylic acid. *Toxic Appl Pharmac* 1959; 1: 229-39.
13. Breddin K, Loew D, Lechner K, Uberla K, Walter E. Secondary prevention of myocardial infarction: Comparison of treatment with acetylsalicylic acid, phenprocoumon or placebo. A multicentre 2 year prospective study. *Int Congr Ser* 1979; 470: 263-8.
14. Breddin K, Loew D, Lechner K, Oberla K, Walter E. The German_Austrian trial. A comparison of acetylsalicylic acid, placebo and phenprocoumon in secondary prevention of myocardial infarction. *Circulation* 1980; 62 (Suppl V): V63-V72.
15. Hirsh J, Dalen JE, Fuster V, Harker LB, Salzman EW. Aspirin and other platelet-active drugs. The relationship between dose, effectiveness and side effects. *Chest* 1992; 102: 327S-36S.
16. Cairns JA, Gent M, Singer J, Finnie KJ, Froggatt GM, et al. Aspirin, sulfinpyrazone, or both in unstable angina. Results of a Canadian multicenter trial. *N Engl J Med* 1985; 313: 1369-75.
17. Canadian Cooperative Study Group. A randomized trial of aspirin and sulfinpyrazone in threatened stroke. *N Engl J Med* 1978; 299: 53-9.
18. Clopath P. The effect of acetylsalicylic acid (ASA) on the development of atherosclerotic lesions in miniature swine. *Br J Exp Path* 1980; 61: 440-3.
19. Coronary Drug Project Research Group. Aspirin in coronary heart disease. *J Chron Dis* 1976; 29: 625-42.
20. Coronary Drug Project Research Group. Aspirin in coronary heart disease. *Circulation* 1980; 62 (Suppl V): V59-V62.
21. Craven LL. Acetylsalicylic acid, Possible preventive coronary thrombosis. *Ann West Med Surg* 1950; 4: 95-9.
22. Craven LL. Prevention of coronary and cerebral thrombosis. *Miss Valley Med J* 1956; 78: 213-5.
23. Czaplicki S, Gietka J, Suzek K. The frequency of coronary heart disease and myocardial infarction in rheumatoid arthritis patients. *Cor Vasa* 1978; 20: 249-54.

24. Danese CA, Voletti CD, Weiss HJ. Protection by aspirin against experimentally induced arterial thrombosis in dogs. *Thrombos Diathes Haemorrh* 1971; 25: 288-96.
25. De Caterina R, Giannessi D, Boem A, Bernini W, Battaglia D, Michelassi C, Dell'Amico F, L'Abbate A, Patrignani P, Patrono C. Equal antiplatelet effects of aspirin 50 or 324 mg/day in patients after acute myocardial infarction. *Thromb Haemostas* 1985; 54: 528-32.
26. De Gaetano G. Primary prevention of vascular disease by aspirin. *Lancet* 1988; 1: 1093-1094.
27. Editorial. Aspirin after myocardial infarction. *Lancet* 1980; 1: 1172-3.
28. Editorial. Trials of drugs for prevention of 'secondary' MIs indecisive. *Hosp Prac* (April) 1980: 53-4.
29. The Dutch TIA Trial Study Group. A comparison of two doses of aspirin (30 mg vs. 283 mg a day) in patients after a transient ischemic attack or minor ischemic stroke. *N Engl J Med* 1991; 325: 1261-6.
30. EDTRS Investigators. Aspirin Effects on Mortality and Morbidity in Patients with Diabetes Mellitus. *JAMA* 1992; 268(10): 1292-1300.
31. Elwood PC, Sweetnam PM. Aspirin and secondary mortality after myocardial infarction. *Lancet* 1979; 2: 1313-5.
32. Farah AE, Rosenberg F. Potential therapeutic application of aspirin and other cyclooxygenase inhibitors. *Br J Clin Pharmac* 1980; 10: 261S-78S.
33. Fields WS, Lemak NA, Frankowski RF, Hardy RJ. Controlled trial of aspirin in cerebral ischemia. *Stroke* 1977; 8: 301-16.
34. Fitzgerald GA, Oates JA, Hawiger J, Maas RL, Jackson R, et al. Endogenous biosynthesis of prostacyclin and thromboxane and platelet function during chronic administration of aspirin in man. *Clin Invest* 1983; 71: 676-88.
35. Flower RJ, Moncada S, Vane JR. Analgesic - antipyretics and anti-inflammatory agents; drugs employed in the treatment of gout. *In: The Pharmacological Basis of Therapeutics*, Chapter 29, 1980, 682-692.
36. Genton E. A perspective on platelet - suppressant drug treatment in coronary artery and cerebrovascular disease. *Circulation* 1980; 62: V111-V121.

37. Analgesic-antipyretic and anti-inflammatory agents: the salicylates. *In: Goodman and Gilman's, The Pharmacological Basis of Therapeutics, 9th Edition, Hardman JG, Limbird LE, Gilman (eds), McGraw-Hill, USA, 1996.*
38. Green LH, Seropian E, Handin RI. Platelet activation during exercise-induced myocardial ischemia. *N Engl J Med* 1980; 302: 193-7.
39. Guslandi M. Gastric toxicity of antiplatelet therapy with low-dose aspirin. *Drugs* 1997; 53: 1-5.
40. Haft JJ. Platelets and coronary artery disease. *Prim Card* 1979; June: 97-104.
41. Hansson L, Zanchetti A, Carruthers GS, Dahlof B, Eimfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerlin S. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. *Lancet* 1998;351: 1755-1762.
42. Harker LA, Slichter SJ. Studies of platelet and fibrinogen kinetics in patients with prosthetic heart valves. *N Engl J Med* 1970; 283: 1302-5.
43. Harris WH, Salzman EW, Athanasoulis CA, Waltman AC, Baum S, De Sanctis RW. Aspirin prophylaxis of venous thromboembolism after total hip replacement. *N Engl J Med* 1977; 297: 1246-9.
44. Harris WH, Salzman EW, Athanasoulis CA, Waltman AC, Baum S, De Sanctis RW. Comparison of warfarin, low molecular-weight dextran, aspirin and subcutaneous heparin in prevention of venous thromboembolism following total hip replacement. *J Bone Joint Surg* 1974; 56: 1552-62.
45. Harrison MJG, Marshall J, Meadows JC, Russell RWR. Effect of aspirin in Amaurosis Fugax. *Lancet* 1971; 2: 743-4.
46. Hennekens CH, Peto R, Hutchison GB, Doll R. An overview of the British and American aspirin studies. *N Engl J Med* 1988; 318: 923-4.
47. Hoffman W, Forster W. Two year Cottbus reinfarction study with 30 mg aspirin per day. *Prostaglandins, Leukotrienes and Essential Fatty Acid* 1991; 44: 159-69.
48. Hoffman W, Nitschke M, Muche J, Kampe W, Handreg W, Forster W. Reevaluation of the Cottbus reinfarction study with 30 mg aspirin per day 4 years after the end of the study. *Prostaglandins, Leukotrienes and Essential Fatty Acids* 1991; 42: 137-9.
49. Hogben AMC, Tocco DJ, Brodie BB, Schanker LS. On the mechanism of intestinal absorption of drugs. *J Pharm Ther* 1959; 125: 275-82.

50. Hsia J, Hamilton WP, Kleiman N, Roberts R, Chaitman BR, Ross AM for the Heparin-Aspirin Reperfusion Trial (HART) Investigators. A comparison between heparin and low-dose aspirin as adjunctive therapy with tissue plasminogen activator for acute myocardial infarction. *N Engl J Med* 1990; 323: 1433-7.
51. Hume M, Bierbaum B, Kurlakose TX, Surprenant J. Prevention of post-operative thrombosis by aspirin. *Amer J Surg* 1977; 133: 420-2.
52. Jakubowski JA, Stampfer MJ, Vaillancourt R, Deykin D. Cumulative antiplatelet effect of low-dose enteric coated aspirin. *Br J Haematol* 1985; 60: 635-42.
53. Jennings JJ, Harris WH, Sarmiento A. A clinical evaluation of aspirin prophylaxis of thromboembolic disease after total hip arthroplasty. *J Bone Joint Surg* 1976; 58: 926-8.
54. Juul-Moller S, Edvardsson N, Jahnmatz B, Rosen A, Sorensen S, Omblus R, for the Swedish Angina Pectoris Aspirin Trial (SAPAT) Group: Double-blind trial of aspirin in primary prevention of myocardial infarction in patients with stable chronic angina pectoris. *Lancet* 1992; 340: 1421-5.
55. Kumpuris AG, Luchi RJ, Waddell CC, Miller RR. Production of circulating platelet aggregates by exercise in coronary patients. *Circulation* 1980; 61: 62-5.
56. Lewis HD Jr, Davis JW, Archibald DG, Steinke WE, Smitherman TC, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. Results of a veterans administration cooperative study. *N Engl J Med* 1983; 309: 396-403.
57. Lindblad B, et al. Does low-dose acetylsalicylic acid prevent stroke after carotid surgery? A double-blind, placebo-controlled randomized trial. *Stroke* 1993; 24:1125-8.
58. Malseed R, Malseed Z. Aspirin: a pharmacologic profile. *Amer J Pharm* 1978; July-Aug: 99-106.
59. McCann RL, Hagen P, Fuchs JCA. Aspirin and dipyridamole decrease intimal hyperplasia in experimental vein grafts. *Ann Surg* 1980; 191: 238-43.
60. McKenna R, Bachmann F, Kaushal SP, Galante JO. Thromboembolic disease in patients undergoing total knee replacement. *J Bone Joint Surg* 1976; 58: 928-32.
61. Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomized trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. *Lancet* 1998;351:233-41
62. Mehta J, Mehta P, Burger C, Pepine CJ. Platelet aggregation studies in coronary heart

- disease. IV. Effect of aspirin. *Atherosclerosis* 1978; 31: 169-75.
63. Mehta P, Mehta J. Platelet function studies in coronary heart disease. V. Evidence for enhanced platelet microthrombus formation activity in acute myocardial infarction. *Am J Cardiol* 1979; 43: 757-60.
 64. Mehta J, Mehta P, Pepine CJ, Contic R. Platelet aggregation studies in coronary heart disease. VII. Effect of aspirin and tachycardia stress on aortic and coronary venous blood. *Am J Cardiol* 1980; 45: 945-51.
 65. Morley J. Mechanism of action of aspirin in inflammation. *Proc Roy Soc Med* 1977; 70: 32-6.
 66. Moschos CB, Haider B, De La Cruz C, Lyons MM, Regan TJ. Antiarrhythmic effects of aspirin during non_thrombotic coronary occlusion. *Circulation* 1978; 57:681-4.
 67. Mundall J, Quintero P, Von Kaulla KN, Harmon R, Austin J. Transient monocular blindness and increased platelet aggregability treated with aspirin. *Neurology* 1972; 22: 280-5.
 68. Orme M. Aspirin all round? *Br Med J* 1988; 296: 307-8.
 69. Orr J, Abbott F, Farrell K, Ferguson S, Sheppard I, and W Godolphin, Interaction between valproic acid and aspirin in epileptic children: Serum protein binding and metabolic effects. *Clin. Pharmacol. Ther.* 1982;31:642-649.
 70. Packham MA, Mustard JF. Pharmacology of platelet affecting drugs. *Circulation* 1980; 62: V26-V41.
 71. Patrignani P, Filabozzi P, Patrono C. Selective cumulative inhibition of platelet thromboxane production by low-dose aspirin in healthy subjects. *J Clin Invest* 1982; 69: 1366-72.
 72. Persantine_Aspirin Reinfarction Study (PARIS) Research Group: The persantine_aspirin reinfarction study. *Circulation* 1980; 62 (Suppl V): V85-V88.
 73. Peto R, Gray R, Collins R, et al. Randomized trial of prophylactic daily aspirin in British male doctors. *Br Med J* 1988; 296: 313-6.
 74. Pick R, Chediak J, Glick G. Aspirin inhibits development of coronary atherosclerosis in cynomolgus monkeys (*Macaca Fascicularis*) fed on atherogenic diet. *J Clin Invest* 1970; 63: 158-62.

75. Relman AS. Aspirin for the primary prevention of myocardial infarction. *N Engl J Med* 1988; 318: 245-6.
76. Renaud S, Godu J. Thrombosis prevention by acetylsalicylic acid in hyperlipemic rats. *CMAJ* 1970; 103: 1037-40.
77. RISC Group. Risk of myocardial infarction and death during treatment with low dose aspirin and intravenous heparin in men with unstable coronary artery disease. *Lancet* 1990; 336: 827-30.
78. Roberts MS, Joyce RM, McLeod LJ, Vial JH, Seville PR. Slow-release aspirin and prostaglandin inhibition. *Lancet* 1986; 1(8490): 1153-4.
79. Ross R, Glomset JA. Pathogenesis of atherosclerosis. *N Engl J Med* 1976; 295: 369-377, 420-5.
80. Roth GJ, Stanford N, Majenus PW. Acetylation of prostaglandin synthase by aspirin. *Proc Nat Acad Sci* 1975; 72: 3073-6.
81. Rowland M, Riegelman S. Pharmacokinetics of acetylsalicylic acid and salicylic acid after intravenous administration in man. *J Pharm Sci* 1968; 57: 1313-9.
82. SALT Collaborative Group. Swedish Aspirin Low-Dose Trial (SALT) of 75 mg aspirin as secondary prophylaxis after cerebrovascular ischaemic events. *Lancet* 1991; 338: 1345-9.
83. Salzman EW, Harris WH, De Sanctis RW. Reduction in venous thromboembolism by agents affecting platelet function. *N Engl J Med* 1971; 284: 1287-92.
84. Schafer A, Handin R. The role of platelets in thrombotic and vascular disease. *Proj Cardio Dis* 1979; 22: 31-52.
85. Smith MJH. Plasma salicylate concentrations after small doses of acetylsalicylic acid. *J Pharm Pharmacol* 1951; 3: 409-14.
86. Soreff J, Johnson H, Diener L. Acetylsalicylic acid in a trial to diminish thromboembolic complications after elective hip surgery. *Acta Orthop Scand* 1975; 46: 246-55.
87. Steering Committee of the Physicians' Health Study Research Group. Preliminary report: findings from the aspirin component of the ongoing Physicians' Health study. *N Engl J Med* 1988; 318: 262-4.
88. UK_TIA Study Group. United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: interim results. *Br Med J* 1988; 296: 316-20.

89. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin-like drugs. *Nature New Biol* 1971; 231: 232-5.
90. Verheugt FWA, van der Loarse A, Funke-Kupper AJ, Sterkman LGW, Galema TW, Roos JP. Effects of early intervention with low-dose aspirin (100 mg) on infarct size, reinfarction and mortality in anterior wall acute myocardial infarction. *Am J Cardiol* 1990; 66: 267-70.
91. Wallentin LC and The Research Group on Instability in Coronary Artery Disease in Southeast Sweden. Aspirin (75 mg/day) after an episode of unstable coronary artery disease: Long-term effects on the risk for myocardial infarction, occurrence of severe angina and the need for revascularization. *J Am Coll Cardiol* 1991; 18: 1587-93.
92. Weiss HJ, Aledort LM, Kochwa S. The effect of salicylates on the hemostatic properties of platelets in man. *J Clin Invest* 1968; 47: 2169-80.
93. Weiss HJ. Antiplatelet therapy (second of two parts). *N Engl J Med* 1978; 298: 1403-6.
94. Wilson PF, D'Agostino RB, Levy D, Belanger AM, Silbershatz H, Kannel W. Predictions of Coronary Heart Disease Using Risk Factor Categories. *Circulation* 1998; 97: 1837-1847.
95. Wright HN. Chronic toxicity studies of analgesic and anti-pyretic drugs and congeners. *Toxicol Appl Pharmacol* 1967; 11: 280-92.
96. Wolinsky H. Atherosclerosis. *Textbook of Medicine* 15th Edition. Philadelphia. W.B. Saunders Co. Vol. 1: Chapter 362, pg. 1218 (1979).
97. Wood MD, Alastair J.J, Aspirin as an antiplatelet drug. *N Engl J Med*. 1994. 330: 1287-1294.
98. Young VP, Giles AR, Pater J, Corbett WEN. Sex differences in bleeding time and blood loss in normal subjects following aspirin ingestion. *Thromb Research* 1980; 20: 705-9.
99. Zekert F, Kohn P, Vormittag E, Poigenfurst J, Thien M. Thromboembolie-prophylaxe mit Acetylsalicylsäure bei Operationen wegen huftgelenksnaher Frakturen Mschr Unfallheilk 1974; 77: 97-11.

